MetLife Investment Management’s Utah Medical Products UTMD Stock Holding History

MetLife Investment Management’s Portfolio UTMD Stock Details UTMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$152K	Hold	2,202	–	–	﹤0.01%	2559
2026 Q1	$137K	Hold	2,202	–	–	﹤0.01%	2399
2025 Q4	$123K	Hold	2,202	–	–	﹤0.01%	2507
2025 Q3	$139K	Hold	2,202	–	–	﹤0.01%	2501
2025 Q2	$125K	Hold	2,202	–	–	﹤0.01%	2427
2025 Q1	$123K	Hold	2,202	–	–	﹤0.01%	2426
2024 Q4	$135K	Hold	2,202	–	–	﹤0.01%	2488
2024 Q3	$147K	Hold	2,202	–	–	﹤0.01%	2442
2024 Q2	$147K	Buy	2,202 +172	+8%	+$11.7K	﹤0.01%	2424
2024 Q1	$144K	Hold	2,030	–	–	﹤0.01%	2363
2023 Q4	$171K	Hold	2,030	–	–	﹤0.01%	2325
2023 Q3	$175K	Hold	2,030	–	–	﹤0.01%	2289
2023 Q2	$189K	Hold	2,030	–	–	﹤0.01%	2311
2023 Q1	$192K	Hold	2,030	–	–	﹤0.01%	2248
2022 Q4	$204K	Hold	2,030	–	–	﹤0.01%	2231
2022 Q3	$173K	Hold	2,030	–	–	﹤0.01%	2393
2022 Q2	$174K	Hold	2,030	–	–	﹤0.01%	2412
2022 Q1	$182K	Buy	2,030 +737	+57%	+$67.8K	﹤0.01%	2402
2021 Q4	$129K	Hold	1,293	–	–	﹤0.01%	2309
2021 Q3	$120K	Buy	+1,293	New	+$114K	﹤0.01%	2360
2021 Q1	–	Sell	-2,002	Closed	-$169K	–	2334
2020 Q4	$169K	Hold	2,002	–	–	﹤0.01%	2071
2020 Q3	$160K	Hold	2,002	–	–	﹤0.01%	1997
2020 Q2	$177K	Hold	2,002	–	–	﹤0.01%	1975
2020 Q1	$188K	Hold	2,002	–	–	﹤0.01%	1736
2019 Q4	$216K	Hold	2,002	–	–	﹤0.01%	1934
2019 Q3	$192K	Hold	2,002	–	–	﹤0.01%	1975
2019 Q2	$192K	Sell	2,002 -4,004	-67%	-$337K	﹤0.01%	2051
2019 Q1	$530K	Buy	6,006 +4,004	+200%	+$352K	﹤0.01%	2010
2018 Q4	$166K	Hold	2,002	–	–	﹤0.01%	2007
2018 Q3	$189K	Hold	2,002	–	–	﹤0.01%	2121
2018 Q2	$221K	Hold	2,002	–	–	﹤0.01%	1885
2018 Q1	$198K	Hold	2,002	–	–	﹤0.01%	1897
2017 Q4	$163K	Buy	+2,002	New	+$156K	﹤0.01%	2031

Other funds holding UTMD

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Minerva Advisors Bala Cynwyd, Pennsylvania $158M AUM 42.05% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $34.3B AUM 22.63% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

MetLife Investment Management's UTMD Position: Q2 2026 in Review

MetLife Investment Management held its Utah Medical Products (UTMD) position steady in Q2 2026 at 2,202 shares worth $152K. The position accounts for ﹤0.01% of the portfolio, ranked #2559.

MetLife Investment Management first reported a position in UTMD in Q4 2017 and has held it in 33 quarters since. The position peaked at $530K in Q1 2019. 114 funds tracked by Wall St. Rank hold UTMD as of Q2 2026.

MetLife Investment Management held 2,202 shares of Utah Medical Products worth $152K as of Q2 2026.
MetLife Investment Management left its Utah Medical Products share count unchanged in Q2 2026.
Utah Medical Products made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #2559 holding.
MetLife Investment Management first reported a position in Utah Medical Products in Q4 2017 and has held it in 33 quarters since.
MetLife Investment Management's Utah Medical Products position peaked at $530K in Q1 2019.
114 funds tracked by Wall St. Rank held Utah Medical Products as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.